Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
GA Wells, A Cranney, J Peterson… - Cochrane database …, 2008 - cochranelibrary.com
Cochrane database of systematic reviews, 2008•cochranelibrary.com
Background Osteoporosis is an abnormal reduction in bone mass and bone deterioration
leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of
drugs, which act to inhibit bone resorption by interfering with the activity of osteoclasts.
Objectives To assess the efficacy of alendronate in the primary and secondary prevention of
osteoporotic fractures in postmenopausal women.
leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of
drugs, which act to inhibit bone resorption by interfering with the activity of osteoclasts.
Objectives To assess the efficacy of alendronate in the primary and secondary prevention of
osteoporotic fractures in postmenopausal women.
Background
Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which act to inhibit bone resorption by interfering with the activity of osteoclasts.
Objectives
To assess the efficacy of alendronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
cochranelibrary.com
以上显示的是最相近的搜索结果。 查看全部搜索结果